Polymorphisms of TREH, IL4R and CCDC26 genes associated with risk of glioma
Abstract Introduction : Glioma is one of the most aggressive human tumors; however, little is known about its genetic risk factors. The role of heredity is likely to be explained by combinations of common low-risk variants. Previous studies have indicated that more than 100 single nucleotide polymor...
Saved in:
Published in | Cancer epidemiology Vol. 36; no. 3; pp. 283 - 287 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier Ltd
01.06.2012
Elsevier Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Abstract Introduction : Glioma is one of the most aggressive human tumors; however, little is known about its genetic risk factors. The role of heredity is likely to be explained by combinations of common low-risk variants. Previous studies have indicated that more than 100 single nucleotide polymorphisms (SNPs) are associated with the risk of glioma. Methods : To further investigate how and to what extent these SNPs contribute to glioma susceptibility in a Chinese population, we analyzed 43 SNPs of 226 glioma patients and 254 normal people in order to evaluate the associations between SNPs and the risk of glioma. Results : Overall, we found three protective alleles for glioma in patients: the allele “G” of rs1801275 in the IL4R gene by allele model (odds ratio [OR], 0.71; 95% confidence interval [CI], 0.50–0.99; P = 0.04) and dominant model (OR, 0.67; 95% CI, 0.46–0.99; P = 0.04) analysis respectively, the allele “T” of rs17748 in the TREH gene by recessive model (OR, 0.48; 95% CI, 0.23–1.01; P = 0.05) analysis, and the allele “G” of rs6470745 in CCDC26 gene by recessive model (OR, 0.48; 95% CI, 0.26–0.89; P = 0.02) analysis. Conclusion : This study provides evidence for three glioma susceptibility genes – TREH, IL4R and CCDC26 – in a Chinese population; this may shed light on molecular markers of glioma susceptibility and could therefore be used as a diagnostic and prognostic marker for glioma patients in clinical study. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
ISSN: | 1877-7821 1877-783X |
DOI: | 10.1016/j.canep.2011.12.011 |